Intraparenchymal haemorrhages as a primary outcome measure - Authors' reply

Benjamin Maïer¹, Jean-Philippe Desilles¹, Mikael Mazighi²; BP-TARGET Investigators

Affiliations

¹ Interventional Neuroradiology Department, Hôpital Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Department of Neurology, Université de Paris, Paris, France; FHU Neurovasc, Paris, France; INSERM U1148, Laboratory of Vascular Translational Science, Paris, France.
² Interventional Neuroradiology Department, Hôpital Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Department of Neurology, Université de Paris, Paris, France; FHU Neurovasc, Paris, France; INSERM U1148, Laboratory of Vascular Translational Science, Paris, France. Electronic address: mmazighi@for.paris.

PMID: 34302779
DOI: 10.1016/S1474-4422(21)00184-8

Comment

Intraparenchymal haemorrhages as a primary outcome measure - Authors' reply

Benjamin Maïer et al. Lancet Neurol. 2021 Aug.

. 2021 Aug;20(8):595-596.

doi: 10.1016/S1474-4422(21)00184-8.

Authors

Benjamin Maïer¹, Jean-Philippe Desilles¹, Mikael Mazighi²; BP-TARGET Investigators

Affiliations

¹ Interventional Neuroradiology Department, Hôpital Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Department of Neurology, Université de Paris, Paris, France; FHU Neurovasc, Paris, France; INSERM U1148, Laboratory of Vascular Translational Science, Paris, France.
² Interventional Neuroradiology Department, Hôpital Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Department of Neurology, Université de Paris, Paris, France; FHU Neurovasc, Paris, France; INSERM U1148, Laboratory of Vascular Translational Science, Paris, France. Electronic address: mmazighi@for.paris.

PMID: 34302779
DOI: 10.1016/S1474-4422(21)00184-8

No abstract available

PubMed Disclaimer

Conflict of interest statement

MM declares consulting activities for Boehringer Ingelheim, Amgen, Air Liquide, and Acticor Biotech. All other authors declare no competing interests.

Comment on

Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
Mazighi M, Richard S, Lapergue B, Sibon I, Gory B, Berge J, Consoli A, Labreuche J, Olivot JM, Broderick J, Duhamel A, Touze E, Qureshi AI, Yavchitz A, Escalard S, Desilles JP, Redjem H, Smajda S, Fahed R, Hébert S, Maïer B, Delvoye F, Boursin P, Maacha MB, Obadia M, Sabben C, Blanc R, Savatovsky J, Piotin M; BP-TARGET investigators. Mazighi M, et al. Lancet Neurol. 2021 Apr;20(4):265-274. doi: 10.1016/S1474-4422(20)30483-X. Epub 2021 Feb 26. Lancet Neurol. 2021. PMID: 33647246 Clinical Trial.
Intraparenchymal haemorrhages as a primary outcome measure.
Goyal M, Ospel JM, Demchuk A, McDonough RV. Goyal M, et al. Lancet Neurol. 2021 Aug;20(8):595. doi: 10.1016/S1474-4422(21)00183-6. Lancet Neurol. 2021. PMID: 34302780 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Intraparenchymal haemorrhages as a primary outcome measure - Authors' reply

Affiliations

Intraparenchymal haemorrhages as a primary outcome measure - Authors' reply

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical